Rise Therapeutics Granted U.S. Patent Supporting Oral Delivery of Targeted Biological Therapy
Rockville, MD. Rise Therapeutics today announced that the U.S. Patent Trademark Office issued a U.S. patent, No. 9,931,390, entitled “Recombinant Lactococcus Lactis expressing Escherichia Coli Colonization Factor Antigen I (CFA/I) Fimbriae and Their Methods of Use.” The patent covers a first-in-class design related to a platform approach to deliver targeted protein therapies orally. This approach can be used to treat a variety of disease indications.
“We plan, through our oral drug delivery approach supported by this patent, to design and develop multiple drug candidates to treat a wide range of diseases,” Dr. Gary Fanger, President and CEO of Rise Therapeutics. “Combining this oral drug delivery technology with new microbiome-related discoveries, the Rise Therapeutics team is initiating development of a new class of novel therapeutics.”
Drug programs being developed by Rise and its partners are based upon Rise Therapeutics’ novel drug delivery platform that enables oral delivery of targeted biological medicines. The platform, called TriPartite X (TPX), is a novel DNA assembly approach that harnesses synthetic biology to enable creation of engineered probiotics to escort targeted protein therapies to the site of action, the intestinal tract. TPX transitions drug development away from regular injections and infusion strategies for a more convenient ‘pill-based’ oral delivery perspective for biological medicines. TPX can be utilized to deliver a variety of proteins for immune modulation, and Rise has interest in exploring applications with additional partners that have protein-based therapeutic candidates they want to develop as orally-available biologics.
About Rise Therapeutics
At the crossroads of the microbiome and immunology, Rise Therapeutics is developing immunological therapies using a unique and proprietary oral delivery platform. Based in Rockville, Maryland, Rise leverages its target discovery expertise to understand microbiota gut biology as it relates to regulation of the immune system. Utilizing these biological discoveries to identify new immune regulatory pathways, Rise develops immune modulatory drugs for therapy of autoimmunity, inflammatory disease, cancer, and infectious disease. With its proprietary Tripartite X (TPX) platform, Rise delivers these first-in-class biological therapies orally. For more information about Rise Therapeutics, please visit www.risetherapeutics.com.